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 Bluetongue virus (BTV) is the causative agent of bluetongue disease (BT), 
which affects domestic and wild ruminants. At the present, 27 different serotypes have 
been documented. Vaccination has been demonstrated as one of the most effective 
methods to avoid viral dissemination. To overcome the drawbacks associated with the 
use of inactivated and attenuated vaccines we engineered a new recombinant BTV 
vaccine candidate based on proteins VP2, VP7, and NS1 of BTV-4 that were 
incorporated into avian reovirus muNS-Mi microspheres (MS-VP2/VP7/NS1) and 
recombinant modified vaccinia virus Ankara (rMVA). The combination of these two 
antigen delivery systems in a heterologous prime-boost vaccination strategy generated 
significant levels of neutralizing antibodies in IFNAR(-/-) mice. Furthermore, this 
immunization strategy increased the ratio of IgG2a/IgG1 in sera, indicating an induction 
of a Th1 response, and elicited a CD8 T cell response. Immunized mice were protected 
against lethal challenges with the homologous serotype 4 and the heterologous serotype 
1 of BTV. All these results support the strategy based on microspheres in combination 
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1. Introduction 
Bluetongue (BT) is a vector-borne viral disease of domestic and wild ruminants 
caused by Bluetongue virus (BTV), one of the most important livestock pathogens. 
(Saegerman et al., 2008). The disease is characterized by vascular injury that results in 
tissue necrosis, hemorrhage, and edema in ruminants (Maclachlan et al., 2009) and 
IFNAR(-/-) mice (Marin-Lopez et al., 2016). BTV belongs to the genus Orbivirus 
within the family Reoviridae with a non-enveloped virion and an icosahedral capsid. 
The genome is composed of double-stranded RNA (dsRNA) distributed in ten 
segments, encoding for seven structural proteins (VP1-VP7) and five/six nonstructural 
proteins (NS1, NS2, NS3/3A, NS4 and NS5) (Ratinier et al., 2011; Roy, 1992; Stewart 
et al., 2015).	The virus is mainly transmitted between ruminant hosts through certain 
species of hematophagous Culicoides (Diptera, Ceratopogonidae) midges (Mellor et 
al., 2000).	To date, 27 serotypes of BTV have been identified (Zientara et al., 2014) 
with two further putative/novel BTV serotypes identified so far (Maan et al., 2015). 
Since 1998 at least 8 serotypes have been detected within the European Union (Zientara 
and Sanchez-Vizcaino, 2013) and the introduction of new BTV serotypes is a 
permanent threat to the region. The constant arrival of new BTV serotypes re-
emphasizes the importance of making multiserotype and more effective vaccines than 
those that are currently available. Although conventional vaccines have controlled or 
limited BTV spreading in the past, they cannot address the need for cross-protection 
among serotypes (Marín-López et al., 2016). Furthermore, modified live virus (MLVs) 
and inactivated vaccines currently used in Europe do not allow the differentiation of 
infected from vaccinated animals (DIVA). 
In previous work in our laboratory, we demonstrated that the immunization of 
IFNAR(-/-) mice with an experimental subunit vaccine based on VP2, VP7, and NS1 
proteins of BTV-4 incorporated into avian reovirus (ARV) muNS-Mi microspheres 
(MS-BTV) and without adjuvant protected against a homologous challenge with a lethal 
dose of BTV-4. Furthermore, the vaccine partially cross-protected against a 
heterologous challenge with a lethal dose of BTV-1 (Marin-Lopez et al., 2014). 
Immunized mice generated significant levels of neutralizing antibodies specific to BTV-
4 and T cell responses, predominantly CD4+. Cellular immune responses, specially 
cytotoxic T lymphocyte responses (CTL) have been demonstrated to be important in 
clearance of homologous and heterologous serotypes of BTV (Jeggo et al., 1985) and in 
vitro studies showed that BTV-specific ovine and murine CTL were cross-reactive 
among serotypes (Jones et al., 1996; Takamatsu and Jeggo, 1989). Furthermore, CD8 T 
cell epitopes have been identified in sheep and the murine model of infection from VP7 
and NS1 proteins of BTV-8 (Rojas et al., 2014; Rojas et al., 2011) and CTL epitopes 
have been described in sheep from VP2 and NS1 proteins of BTV-1 (Andrew et al., 
1995; Janardhana et al., 1999).  
In the present work, we developed a new vaccination strategy based on a 
heterologous prime-boost strategy with the particulate subunit vaccine MS-BTV and 
with the viral vaccine vector MVA expressing BTV antigens. Particulate immunogens 
are best for stimulating both humoral and cellular immune responses (Roy, 1996). 
Moreover, they are cheap, very stable, do not require the use adjuvants due to their 
intrinsic adjuvant effect, and are biologically safe. On the other hand, it has been 
described the use of rMVAs as a potent inductor of CD8 T cellular immune responses 
when used as a heterologous boost vaccination following a strong priming agent 
expressing the same antigen (Cottingham and Carroll, 2013; Whelan et al., 2009). In 
order to improve the serotype cross-protection of the experimental vaccine, we focused 
the vaccine composition on the VP2, VP7 and NS1 proteins of BTV-4. These proteins 
have been generally described to induce cross-serotype helper T-cell or cytotoxic T-cell 
responses. 
 
2. Materials and methods 
 
2.1. Virus and cells.  
Chicken embryo fibroblasts (DF-1) (ATCC, Cat. No. CRL-12203) and Vero 
(ATCC, Cat. No. CCL-81) cells were grown in Dulbecco´s modified Eagle´s medium 
(DMEM) supplemented with 2mM glutamine, 10% heat-inactivated fetal bovine serum 
(FBS) and antibiotics. Insect cells High Five (Invitrogen) were grown in TC-100 
medium supplemented with 2mM glutamine, 10% heat-inactivated fetal bovine serum 
(FBS) and antibiotics. BTV serotype 4 (Spain2005/05) (BTV-4) and serotype 1 
(ALG2006/01) (BTV-1) were used in the experiments. BTV and MVA virus stocks and 
titrations were performed as previously described (Calvo-Pinilla et al., 2009). 
2.2. Mice.  
IFN α/βRo/o IFNAR(-/-) 129/Sv mice and wild type 129/Sv mice were purchased 
from B&K Universal Ltd UK. Eight-week old male mice were used throughout. Upon 
reception, the mice were held for 7 days for acclimatization under pathogen-free 
conditions in the biosafety level 3 (BSL3) animal facility at the Centro de Investigación 
en Sanidad Animal (INIA-CISA), Madrid. All experiments with live animals were 
performed under the guidelines of the European Community (86/609) and were 
approved by the ethical review committee at the INIA-CISA and Comunidad de Madrid 
(Permit number: PROEX 037/15). 
 
2.3. Generation of muNS-Mi microspheres (MS-VP2/VP7/NS1), and recombinant MVAs 
expressing VP2, VP7 and NS1 BTV-4 proteins (rMVA-VP2/VP7/NS1). 
The production and purification of muNS-Mi-VP2/VP7/NS1 microspheres using 
the baculovirus expression system and the generation of rMVA-VP2/VP7/NS1 have 
been previously described (Brandariz-Nunez et al., 2010; Marin-Lopez and Ortego, 
2016; Marin-Lopez et al., 2014).  
 
2.4. In silico T CD8 epitope prediction 
Amino acid sequences for the non-structural NS1 protein (NCBI accession 
number: AM778441.1) and structural VP2 protein of BTV-4 (Spain2005/05) were 
analized using three prediction algorithms available on the web: Immuno Epitope 
DataBase (IEDB Analysis Resource) (www.iedb.org), SYFPEITHI (www.syfpeithi.de),  
and BIMAS (www.bimas.cit.nih.gov/) for the H-2-Db MHC class I for 129/Sv mice to 
identify T CD8 epitopes that could be good binders to H-2-Db MHC. Theoretical T-cell 
epitopes were chosen by a combination of the best score in these databases (table 1).  
 
2.5. Peptides 
The selected peptides (table 1) were purchased from Proteogenix (Schiltigheim, 
France) and Sigma-Aldrich (The Woodlands, USA). Peptides were >95 % pure 
(HPLC%). They were re-constituted in DMSO or Dimetilformamide according to the 
manufacturer instructions and kept frozen at −20 °C until use. All peptides were diluted 
in culture media: RPMI-1640 (Gibco, GreenIsland, NY) containing 10 % (v/v) heat-
inactivated fetal bovine serum (FBS), 1 % (v/v) antibiotic-antimycotic solution (Gibco), 
1% (v/v) non-essential aminoacids and 2 mM glutamine (Gibco).  
 
2.6. Studies of cellular immune response in IFNAR(-/-) mice.  
Three groups of IFNAR(-/-) mice (n=4) were immunized following a 
homologous prime-boost regimen with rMVA-VP2, rMVA-NS1 or MVA-wild type 
(non-immunized group) three weeks apart. All animals were sacrificed at 14 days post-
booster and their spleens were harvested for analysis by ELISPOT and intra-cellular 
cytokine staining (ICCS) as previously described (de la Poza et al., 2015; Marin-Lopez 
et al., 2014).  
 
2.7. Prime-boost immunization and challenge with BTV in IFNAR(-/-) mice.  
Groups of five IFNAR(-/-) mice were immunized by homologous prime-boost 
vaccination with MS-VP2/VP7/NS1 (50 µg of each per mice) or by heterologous prime-
boost vaccination with MS-VP2/VP7/NS1 (50 µg/mice)  and rMVA-VP2/VP7/NS1 
(107 PFU/mice) , or prime-boosted with MS (50 µg/mice) and 3x107 PFU per mice of 
MVA-wt (non-immunized) administered by intraperitoneal injection three weeks apart. 
Two weeks after the second immunization all mice were subcutaneously inoculated 
with 5x102 PFUs of BTV-4 or 102 PFUs of BTV-1. Clinical data were recorded as 
described previously (de la Poza et al., 2013). 
 
2.8. Detection of BTV-4 and BTV-1 in blood.  
Whole blood was collected in EDTA from all animals at regular intervals after 
viral challenge. The viruses were released from whole blood by three freeze/thaw cycles. 
The amount of infectious virus was measured by plaque assay on Vero cells. 
 
2.9. BTV-4 and BTV-1 neutralizing antibody detection in immunized mice by viral 
neutralization test (VNT) and isotyping ELISA assay for antibodies specific of VP2 
protein. 
 The VNT was used to determine neutralizing antibody titers against BTV-4 prior 
infection. For plaque reduction assays, 2 fold dilutions of sera were mixed with 100 PFU 
of BTV-4, incubated for 1 hour at 37 °C and then plated into monolayers of Vero cells. 
After 1 hour, agar overlays were added and the plates were incubated for 5 days. The titer 
was determined as the highest dilution that reduced the number of plaques by 50%. 
Isotype determination was performed by ELISA using a mouse immunoglobin 
isotyping kit (Biorad), using a fixed dilution of sera (1/50). As antigen in this assay, 96 
well plate was coated with 150 ng/well of recombinant VP2 protein from BTV-4 





3.1. Heterologous prime boost immunization with MS-VP2/VP7/NS1 and rMVA-
VP2/VP7/NS1 protects IFNAR(-/-) mice against homologous BTV-4. 
With the aim to analyze the efficacy of the combination of MS-VP2/VP7/NS1- 
rMVA-VP2/VP7/NS1 as immunogen to protect against BTV-4 infection, two groups of 
mice were immunized with MS-VP2/VP7/NS1. Three weeks apart, one group of mice 
was boosted with rMVA-VP2/VP7/NS1 and the other group received a second 
immunization with MS-VP2/VP7/NS1. A third group of mice was primed with MS and 
boosted with MVA-wt (non-immunized group). Two weeks after the second 
immunization, mice were challenged subcutaneously with 5x102 PFUs of BTV-4. All 
non-immunized animals showed clinical signs (the most severe signs, eye swelling, 
lethargy and hypothermia appeared at day 4) and died between days 4 to 5 post-
infection. In contrast, 100% of the animals immunized with MS-VP2/VP7/NS1 or the 
combination of MS-VP2/VP7/NS1 with rMVA-VP2/VP7/NS1 did not show clinical 
signs throughout the experiment and they were completely protected against the lethal 
challenge with BTV-4 (Fig 1A). The titers of infectious virus recovered in the blood 
after challenge with BTV-4 were determined in all animals by plaque assay and titers up 
to 3.3±1.0 x 102 PFU/ml were observed at day 3 post-challenge in non-immunized 
animals (Fig 1B).  Viremia was not detected in the immunized mice.  
 
3.2. Prime boost immunization with MS-VP2/VP7/NS1 and MS-VP2/VP7/NS1+rMVA-
VP2/VP7/NS1 elicits neutralizing antibodies against BTV-4 in IFNAR(-/-) mice 
increasing the ratio IgG2a/IgG1.  
In order to analyze the humoral immune response elicited in mice immunized with the 
homologous and the heterologous strategies, virus neutralization test (VNT) and 
isotyping ELISA assay were performed using the sera of immunized and non-
immunized animals collected 2 weeks after the booster treatment. Similar titers of BTV-
4 neutralizing antibodies were observed in the sera with a VNT50 of 1.825±0.14 and 1.9 
in MS-VP2/VP7/NS1+rMVA-VP2/VP7/NS1 and MS-VP2/VP7/NS1 immunized mice, 
respectively (Fig 2A). Neutralization activity against BTV-4 was not detected in serum 
of non-immunized mice (VNT50≤ 0.6) at the analyzed time. This observation revealed 
that combining microspheres and recombinant MVAs expressing BTV antigens 
achieved similar high levels of neutralizing antibodies to those induced by microspheres 
alone. 
Sera analyzed by ELISA showed an increase in the induction of IgG subtypes 1, 
2a and 2b in the animals boosted with rMVA-VP2/VP7/NS1 compared with those 
immunized with two doses of MS-VP2/VP7/NS1 (Figure 2B). Furthermore, the 
IgG2a/IgG1 ratio was clearly increased in the group boosted with MVA compared to 
the group immunized with two doses of microspheres (Figure 2C). These data indicate 
that the introduction of recombinant MVAs in the vaccine composition improve the 
humoral response induced just by microspheres, enhancing the ratio of IgG2a/IgG1, 
suggesting an activation of a Th1-biased immune response. 
 
3.3. MS-VP2/VP7/NS1+rMVA-VP2/VP7/NS1 immunization elicits strong cellular 
immune response. 
To further analyze the cellular immune response elicited by the MS-
VP2/VP7/NS1+ rMVA-VP2/VP7/NS1 vaccine, the amount of IFN-γ-producing spleen 
cells after the immunizations was determined by ELISPOT. IFNAR(-/-) mice were 
immunized by prime-boost vaccination with MS-VP2/VP7/NS1, MS-rMVA-
VP2/VP7/NS1 or MS (control), administered three weeks apart. Two weeks after the 
second immunization spleens were harvested and the splenocytes were stimulated with 
MS, MS-VP2, MS-VP7, or MS-NS1 in ELISPOT plates. Animals immunized with the 
combined strategy significantly increased the level of IFN-γ producing cells after 
stimulation when compared to the group immunized with MS or the non-immunized 
group (Figure 3). 
 
3.4.  Prediction and assessment of peptide binding from VP2 and NS1 protein to H-2-
Db haplotype as T CD8 epitopes. 
MVA vaccines are expected to induce a strong CD8+ T cell immune response. 
To identify epitopes triggering virus specific CD8+ T cell responses we used a 
combination of three epitope prediction algorithms and 6 peptides from VP2 and 4 
peptides from NS1 proteins from BTV-4 were selected and synthetized (Table 1). The 
ability of these peptides to stimulate the proliferation of IFNγ positive CD8+ T cells and 
to induce the expression of CD107a on the surface of this population/ to bind H-2 Db 
and Kb molecules was assessed by ICCS assay in splenocytes from immunized animals 
with VP2 or NS1 proteins vectorized through recombinant MVAs. None of the six VP2 
selected peptides induced significant levels of IFN-γ in CD8+ T cells in the immunized 
animals after in vitro stimulation. (Figure 4A).  In contrast, one of the four NS1 selected 
peptides, NS1-152 induced a significant recall INFγ response in CD8+ T cells from the 
immunized animals (Figure 4B). These data confirm that NS1-152 peptide is a CD8 
epitope in the 129 mouse strain. We next examined the ability of NS1-152 peptide to 
induce the expression of CD107a on the surface of IFN-γ positive CD8+ T cells, as a 
surface marker of CTL degranulation.  The NS1-152 peptide significantly induced the 
presence of CD107a on the surface of restimulated CD8+ T cells indicating that NS1-
152-specific CD8+ T cells display CTL activity (Figure 4C). These results suggest that 
NS1-152 is an immunodominant epitope for CD8+ T cell responses in IFNAR(-/-) mice. 
 
3.5. MS-VP2/VP7/NS1+rMVA-VP2/VP7/NS1 immunization induces strong CD8+ T cell 
immune response and promotes cytotoxic activity.  
 To assess the phenotype of the BTV-specific IFNγ producing cells after in vitro 
restimulation observed by ELISPOT assay, we immunized mice with MS-
VP2/VP7/NS1+rMVA-VP2/VP7/NS1. T cell immune responses were measured by 
ICCS after the stimulation of splenocytes with the NS1-152 peptide. Re-stimulation 
with the peptide induced high expression of IFNγ by CD8+ T cells in the group of mice 
boosted with rMVA-VP2/VP7/NS1 (Figure 5A). Furthermore, the level of CD8+ T cells 
secreting CD107 augmented upon re-stimulation with NS1-152 peptide in this group of 
animals (Figure 5B). These data suggest that the booster with rMVA-VP2/VP7/NS1 of 
animals primed with MS-VP2/VP7/NS1 elicits an specific CD8+ T cell response, 
exhibiting marked cytotoxic activity  
 
3.6. Heterologous prime boost immunization with MS-VP2/VP7/NS1+rMVA-
VP2/VP7/NS1 protects IFNAR(-/-) mice against heterologous BTV-1 infection 
In order to analyze the efficacy of the combination of MS-VP2/VP7/NS1- 
rMVA-VP2/VP7/NS1 as a vaccine candidate against multiple serotypes of BTV, one 
group of animals was immunized following a prime-boost strategy, while a second 
group was primed with MS and boosted with MVA-wt (non-immunized mice). Both 
groups were challenged with a lethal dose of BTV-1. Non-immunized animals died 
between day 5 and 6 post-infection, showing the most severe clinical signs at days 4 and 
5 and a peak of viraemia at day 5. In contrast, all immunized animals survived after 
challenge and they did not show clinical signs or viraemia after infection (Figure 6). 
These results indicate that the heterologous prime-boost immunization with MS-
VP2/VP7/NS1 and rMVA-VP2/VP7/NS1 reaches the levels of protection conferred by 
the homologous immunization against BTV-4 achieving a 100% of survival and also 
provides a total protection in absence of remarkable clinical signs and viraemia against 
the heterologous challenge with BTV-1. 
 
4. Discussion 
Current BT vaccines commercially available include both live attenuated and 
inactivated vaccines. They are effective but serotype specific and incompatible with 
serological assays to differentiate infected from vaccinated animals. In the last years, 
new experimental DIVA vaccines are being developed trying to generate broad cross-
protection among BTV serotypes.  
In previous work, we developed a subunit BTV vaccine candidate based on the 
proteins VP2, VP7, and NS1 of BTV-4 incorporated into avian reovirus muNS-Mi 
microspheres. IFNAR(-/-) mice immunized with MS-VP2/VP7/NS1 without adjuvant 
generated significant levels of neutralizing antibodies specific of BTV-4,  a specific  
CD4 T cell response, and immunized mice were fully protected against an homologous 
challenge with a lethal dose of BTV-4 and partially protected against the heterologous 
BTV-1 (Marin-Lopez et al., 2014). In the present work, we combined this subunit 
vaccine with rMVAs expressing the same BTV antigens in a prime-boost regimen to 
improve the protection against heterologous serotypes of BTV. The results show that 
the prime boost immunization with MS-VP2/VP7/NS1 and rMVA-VP2/VP7/NS1 
confers total protection against a homologous challenge with BTV-4 and heterologous 
with BTV-1 in IFNAR(-/-) mice. This new strategy elicits similar levels of neutralizing 
antibodies specific of BTV-4 that the strategy based only in microspheres. Interestingly, 
the boost with rMVA-VP2/VP7/NS1 increases IgG2a and IgG2b antibody levels in sera 
and enhances the ratio of IgG2a/IgG1, suggesting that the rMVA-VP2/VP7/NS1 booster 
stimulate a Th1-type immune response.  
Antibody isotypes play different roles in antiviral immunity. Influenza vaccines 
that stimulate IgG1 and IgG2a antibody subclasses induce better protection that those 
that induce only IgG1 with neutralizing activity (Huber et al., 2006). IgG2A antibodies 
are better suited to induce antibody-mediated cell cytotoxic responses and complement 
mediated responses (Liu et al., 2016; Tjiam et al., 2015; Yendo et al., 2016) which have 
been shown to contribute to the clearance of viruses from infected hosts (Huber et al., 
2001). Although there are not studies about the role of the different isotypes in the BTV 
protection, these should be addressed in order to rationally improve BTV vaccine 
strategies. 
Cellular immune responses, specially CTL have been demonstrated to be 
important in the clearance of homologous and heterologous serotypes of BTV (Jeggo et 
al., 1985) and MVA has been described as a potent inductor of CD8 T cell responses 
when used as heterologous boost vaccination following a strong priming agent 
expressing the same antigen (Cottingham and Carroll, 2013; Whelan et al., 2009). 
Previous work in our laboratory using rMVA as a boost in the vaccination strategy 
showed that the heterologous DNA/rMVA prime-boost immunization expressing VP2, 
VP7, and NS1 BTV-4 proteins protected IFNAR(-/-) mice against heterologous 
challenges with BTV-1 and BTV-8, and reduced viraemia significantly in sheep 
infected with the heterologous BTV-8 (Calvo-Pinilla et al., 2014; Calvo-Pinilla et al., 
2012). In this work, ELISPOT assay showed that splenocytes of mice boosted with 
rMVA-VP2/VP7/NS1 elicited stronger cellular immune response than mice immunized 
twice with MS-VP2/VP7/NS1. To better analyze the cellular response phenotype 
induced by the BTV antigens included in the experimental vaccine and find 
immunodominant epitope(s) to CD8+ T cell responses we studied in silico and in vivo 
the presence of CD8 epitopes in proteins VP2 and NS1 of BTV-4. Although CD4 and 
CD8 epitopes have been described for the VP7 protein of BTV-8 in mice and sheep 
(Rojas et al., 2011), we focused the study in proteins VP2 and NS1 where CTL epitopes 
have been described in BTV immunized sheep (Andrew et al., 1995; Janardhana et al., 
1999). None of the six predicted VP2 peptides were capable of eliciting IFN-γ 
production in splenocytes from rMVA-VP2 immunized mice. In contrast, one peptide 
NS1-152 of NS1 protein was identified as a CD8+ T cell epitope that induced the 
expression of IFNγ and CD107a in CD8+ T cells, a marker of cytotoxic activity. 
Importantly, NS1-152 epitope is conserved among all BTV serotypes and it has been 
also previously characterized as a T cell epitope in sheep and C57BL/6 mice (Rojas et 
al., 2014).  
Intracellular cytokine staining studies showed that peptide NS1-152 induced the 
activation of CD8+ T cells and CTLs in vivo in animals boosted with rMVA-
VP2/VP7/NS1, in contrast with previous observations where the immunization with  
MS-VP2/VP7/NS1 predominantly induces a CD4+ T cell response (Marin-Lopez et al., 
2014). In addition, 100% of the MS- rMVA-VP2/VP7/NS1 vaccinated IFNAR(-/-) mice 
survived to the challenge with the heterologous virus BTV-1 and viraemia was not 
observed in immunized animals after BTV-1 challenge.  
In summary, the combination of microspheres and rMVA in a vaccination 
strategy improves the cellular immune response and cross-protection capacity of the 
experimental BTV subunit vaccine based on microspheres. We show that vaccination of 
IFNAR(-/-) mice with MS/rMVA expressing VP2, VP7, and NS1 proteins of BTV-4 
achieves protective homotypic and heterotypic immunity and protection against 
homologous and heterologous infection with BTV-4 and BTV-1. This new experimental 
strategy is an attractive approach to generate new effective, safe and cross-protective 
marker vaccines again the multiple BTV serotypes. 
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 Figure 1. Protection of MS-rMVA-VP2/VP7/NS1 vaccinated IFNAR(-/-) mice 
against a lethal challenge with BTV-4. Mice (8 weeks old, 5 per group) were 
immunized by prime-boost vaccination with MS-VP2/VP7/NS1 or heterologous MS-
rMVA-VP2/VP7/NS1. Two weeks after immunization all mice were subcutaneously 
inoculated with 5x102 PFUs of BTV-4 (lethal dose). (A) Survival rates of immunized 
and non-immunized IFNAR(-/-) mice after inoculation with BTV-4. The mice were 
observed every 24 h for 15 days. (B) Titers of BTV-4 recovered in blood of immunized 
and non-immunized IFNAR(-/-) mice after challenge. Each point represents the mean 
values of the viral titer of five animals, and standard deviations are shown as error bars.  
 
Figure 2. Humoral response observed in IFNAR(-/-) mice vaccinated with MS-
VP2/VP7/NS1 or   MS-rMVA-VP2/VP7/NS1.  (A) Neutralizing antibodies specific of 
BTV-4 were analyzed in sera of immunized mice by VNT. Neutralization titers at day 
15 post-boost treatment in sera of animals immunized with MS-VP2/VP7/NS1 or   MS-
rMVA-VP2/VP7/NS1 are shown. Means are presented as bars and standard deviations 
are shown as error bars. Asterisks (*) indicate statistically significant differences 
(P<0.05) between immunized and non-immunized mice, calculated by signed rank test. 
(B) IgG1 and IgG2a, IgG2b, IgG3, and IgM antibody levels were measured in 15 post-
booster treatment pools of sera of animals immunized with MS-VP2/VP7/NS1 or MS-
rMVA-VP2/VP7/NS1 by ELISA. (C)  IgG2a/IgG1 O.D. ratio.	
 
Figure 3. ELISPOT assays measuring IFN-γ-secreting T cells in the spleen of 
immunized IFNAR(-/-) mice. Mice were immunized with MS-VP2/VP7/NS1 or MS-
rMVA-VP2/VP7/NS1 as described in Materials and Methods. Splenocytes were 
harvested at day 14 post-boost. Mice inoculated with MS were used as non-immunized 
controls. Bars represent the IFN-γ spot-forming cells (SFC) mean number ± standard 
deviation within each group. 10µg of each protein (MS, MS-VP2, MS-VP7, and MS-
NS1) per well were used as stimulus in each experiment.  
 
Figure 4. Membrane labelling of CD107a and intracellular staining of IFN-γ in T 
CD8+ cells of MVA-VP2 or MVA-NS1 immunized IFNAR(-/-) mice. Two weeks 
after the second immunization, spleens were harvested and the splenocytes were 
stimulated with 10 µg/ml of each peptide. Membrane CD107a and intracellular IFN-γ 
production was analyzed in CD8-positive cells by flow cytometry. Black bars: mice 
immunized with MVA-VP2 or MVA-NS1; grey bars: mice immunized with MVA-wt. 
The results represent the average of 4 mice ± SEM. Asterisks represent significant 
difference between samples, calculated by Man-Whitney non parametric test (p≤0.05). 
 
Figure 5. Membrane labelling of CD107a and intracellular staining of IFN-γ in T 
CD8+ cells of MS-VP2/VP7/NS1 or MS-rMVA-VP2/VP7/NS1 immunized IFNAR(-
/-) mice. Two weeks after second immunization, spleens were harvested and the 
splenocytes were stimulated with 10 µg/ml of peptides 152 and 14 from NS1. At 5 h 
post-stimulation, intracellular IFN-γ production and labeling of CD107a were analyzed 
in CD8-positive cells by flow cytometry. Grey bars: peptide NS1-14; black bars: 
peptide NS-152. The results represent the average of 4 mice ± SD. Asterisks represent 
significant difference between immunized and non-immunized mice, calculated by 
Man-Whitney non parametric test (p≤0.01). 
 
Figure 6. Protection of MS-rMVA-VP2/VP7/NS1 vaccinated IFNAR(-/-) mice 
against a BTV-1 challenge. Mice (8 weeks old, 5 per group) were immunized twice by 
homologous prime-boost vaccination with MS-rMVA-VP2/VP7/NS1 administered 3 
weeks apart. Non-immunized group was immunized with MS-rMVA and used as a 
control. Two weeks after the second immunization all mice were subcutaneously 
inoculated with 102 PFUs of BTV-1. (A) Survival rates of immunized and non-
immunized IFNAR(-/-) mice after inoculation with BTV-1. The mice were observed 
every 24 h for 15 days. (B) Titers of BTV-1 recovered in blood of immunized and non-
immunized IFNAR(-/-) mice after challenge. Each point represents the mean values of 
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Table 1. Peptides selected from the epitope prediction in H-2 Db haplotype.  
Protein Position Sequence IEDB SYFPEITHI BYMAS 
      VP2 
147 IYYDYFPL 0.3 - - 
694 YLIQNSTGL 0.8 25 720.000 
731 LNVINFLPL 0.5 23 720.000 
743 VQDNISYW 0.8 - - 
782 KSFYNFIRF 1.4 23 3120 
139 AKTANADTI 0.4 26 220.000 
       NS1 
125 SALVNSERV 0.2 28 51.480 
152 GQIVNPTFI 0.2 28 720.000 
14 YANATRTFL 0.7 16 2.600 
222 IQLINFLRM 0.2 25 792.000 
Using a combination of three epitope T prediction algorithms (IEDB, SYFPEITHI and 
BYMAS), peptides from VP2 and NS1 proteins of BTV-4 were selected and 
synthesized.	
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